Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESCUE: Continuous Temozolomide in Recurrent Glioma
NCT00392171Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2006
- Primary completion
- Sep 2009
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in malignant glioma, sponsored by Merck & Co. Primary endpoint: Percentage of Participants Surviving at Six Months of Treatment Without Evidence of Disease Progression at 6 months. Started Jun 2006; status: completed.
02
Drugs
temozolomide
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00392171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00392171.